The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
Phase: NA
Conditions: Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
Sponsor: HistoSonics, Inc.

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
1 
 
Oﬃcial Title: The HistoSonics System for treatment of primary and metastatic liver tumors using 
histotripsy (#HOPE4LIVER EU/UK) 
NCT Number: NCT04573881 
Protocol Date: February 7, 2022 (CSP1473 Revision D) 
 
 

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
2 
 
Title 
The HistoSonics System for treatment of primary and metastatic liver tumors using 
histotripsy (#HOPE4LIVER EU/UK) 
Clinical Investigation 
Protocol Identification 
Code 
#HOPE4LIVER EU/UK Sponsor Clinical Study Number: CSP1473 Revision D (07Feb2022) 
ClinicalTrials.gov Identifier: NCT04573881 
EUDAMED: CIV-20-10-034904 
Trial Purpose 
The #HOPE4LIVER clinical trial data will be utilized to gain approval in commercializing 
the HistoSonics System. 
Trial Design  
This trial is a single arm, non-randomized prospective trial. Following histotripsy 
treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index 
procedure to determine technical success. Subjects will then be followed for 30 days. 
Additionally, subjects will be evaluated at 6 months and followed annually for up to five 
(5) years post-index procedure. 
Trial Population 
Subjects who are 18 years of age or older with a diagnosis of primary or metastatic 
(from other primary cancers) liver cancer. 
Objective 
The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System 
for the treatment of primary or metastatic tumors located in the liver. 
Device Name  
HistoSonics System (System) 
IDE Indications for Use 
The HistoSonics System (System) is intended for the destruction of liver tissue using 
histotripsy, a non-thermal, mechanical process using focused ultrasound. 
Enrollment 
Up to forty-five (45) subjects enrolled targeting forty (40) evaluable subjects at up to 
seven (7) European clinical sites 
Duration of Trial 
The duration of this trial is expected to be approximately six and a half (6.5) years. 
Primary Endpoints 
Co-primary endpoints: 
1. Efficacy: Technical success as determined, at ≤36 hours post-index procedure, by 
evaluating the histotripsy treatment size and coverage. Technical success is defined 
as the treatment volume/treatment dimensions being greater than or equal to the 
targeted tumor with complete tumor coverage, via CT or MR imaging. [Core Lab 
Adjudicated] [≤36 hours post-index procedure] 
2. Safety: Index procedure related major complications, including device-related 
events, defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 
3 or higher toxicities, up to 30 days post index-procedure  
[Clinical Events Committee Adjudicated] [30-Day post-index procedure] 
Results must be positive for both co-primary endpoints for the trial to be considered 
successful. 
Secondary Endpoints 
Efficacy:  
1. Technique Efficacy: defined as the lack of a nodular or mass-like area of 
enhancement within or along the edge of the treatment volume assessed via MR or 
CT imaging at 30-days post index-procedure [Core Lab Adjudicated] 
Safety: 

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
3 
 
1. All adverse events reported within 30 days of index-procedure [Clinical Events 
Committee Adjudicated] 
Follow-Up Visits 
All enrolled subjects will have a 14-day, 30-day, 6-month, and annual post-index 
procedure (1, 2, 3, 4, 5 year) follow up assessment/visit or until the trial is closed, 
whichever comes first. 
General Inclusion 
 
Subjects are eligible for the trial if all the following criteria are met: 
1. Subject is ≥18 years of age  
2. Subject has signed the Ethics Committee (EC) or Institutional Review Board (IRB) 
approved trial Informed Consent Form (ICF) prior to any trial related 
tests/procedures and is willing to comply with trial procedures and required follow-
up assessments  
3. Subject is diagnosed with hepatocellular carcinoma (HCC) or liver metastases (mets) 
from other primary cancers 
• 
Subject that is an HCC patient must have a targetable lesion(s) which meets the 
United Network for Organ Sharing and Organ Procurement and Transplantation 
Network (UNOS-OPTN) class 5 diagnostic criteria for HCC  
• 
Subject that is diagnosed with liver metastases must have prior diagnosis of 
primary tumor or metastatic tumor to identify the primary cancer type. 
Subjects must have untreated new or growing liver tumor(s) radiologically 
consistent with metastases. Note: A biopsy is required to confirm metastatic 
disease and the pathological results must be obtained prior to the index 
procedure (does not need to be a targeted tumor(s)) 
4. Subject is able to undergo general anesthesia 
5. Subject has a Child-Pugh Score of A or B (up to B8) 
6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 
grade 0-2 at baseline screening 
7. Subject meets the following functional criteria, ≤7 days prior to the planned index-
procedure date: 
• 
Liver function: Alanine transaminase (ALT) <2.5x upper limit of normal (ULN) 
and Aspartate transaminase (AST) <2.5x ULN and bilirubin <2.5 ULN, and 
• 
Renal function: serum creatinine <2x ULN, and 
• 
Hematologic function: neutrophil count >1.0 x 10^9/L and platelet >50 x 10^9/L 
8. Subject has an International Normalized Ratio (INR) score of <2.0, ≤7 days prior to 
the planned index procedure date 
9. Subject has not responded to and/or has relapsed and/or is intolerant of other 
available therapies including locoregional therapies, chemotherapy, 
immunotherapy and targeted therapies. 
Imaging Inclusion 
10. The tumor(s) selected for histotripsy treatment must be ≤3 cm in longest diameter 
11. Subject has an adequate acoustic window to visualize targeted tumor(s) using 
ultrasound imaging 

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
4 
 
12. Subject has a maximum of three (3) tumors to be treated with histotripsy during the 
index procedure, regardless of how many tumors the subject has. 
Note: If the subject is treated with surgical resection prior to the index procedure, 
the resection must be performed ≥2 weeks prior to the planned index-procedure 
date 
General Exclusion 
 
Subjects are not eligible for participation in the trial if any of the following criteria are 
met: 
1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the 
trial period  
2. Subject is enrolled in another investigational trial and/or is taking investigational 
medication and/or has been treated with an investigational device ≤30-days prior to 
planned index procedure date  
3. In the Investigator’s opinion, the subject has co-morbid disease(s) or condition(s) 
that would cause undue risk and preclude safe use of the HistoSonics System 
4. Subject has a serum creatinine >2.0 mg/dL or estimated glomerular filtration rate 
(EGFR) <30, unless on dialysis 
5. Subject has major surgical procedure or significant traumatic injury ≤2 weeks prior 
to the planned index procedure or not fully recovered (CTCAE grade 1 or better) 
from side effects/complications of such procedure or trauma 
6. Subject has not recovered to Common Terminology Criteria for Adverse Events 
(CTCAE) grade 1 or better from any adverse effects (except alopecia, fatigue, 
nausea, vomiting and peripheral neuropathy) related to previous anti-cancer 
therapy 
7. Subject has a history of, or suspected to have, bleeding disorders that are 
uncorrectable. 
8. Subject has a coagulopathy that is uncorrectable   
9. Subject has a planned cancer treatment (e.g. resection, chemotherapy, etc.) after 
the planned index-procedure date and prior to completion of the 30-day follow-up 
visit  
10. Subject has previous treatment with bevacizumab that has not been discontinued 
>40 days prior to the planned index-procedure date 
11. Subject has planned bevacizumab treatment prior to completion of the 30-day 
follow-up visit  
12. Subject has previous treatments with chemotherapy and/or radiotherapy that has 
not been discontinued ≥2 weeks prior to the planned index-procedure date and has 
not recovered (CTCAE grade 1 or better) from related toxicity (except alopecia and 
peripheral neuropathy)  
13. Subject has previous treatment with immunotherapies that has not been 
discontinued ≥4 weeks prior to the planned index-procedure date and has not 
recovered from related toxicity (CTCAE grade 1 or better) 
14. Subject has a life expectancy less than six (<6) months 

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
5 
 
15. In the opinion of the Investigator, histotripsy is not a treatment option for the 
subject  
16. Subject has a concurrent condition that, in the investigator’s opinion, could 
jeopardize the safety of the subject or compliance with the protocol  
17. Subjects’ tumor(s) is not treatable by the System’s working ranges (refer to User 
Manual) 
18. Subject has a known sensitivity to contrast media and cannot be adequately pre-
medicated 
19. Subjects’ targeted tumor(s) has/have had prior locoregional therapy (e.g. ablation, 
embolization, radiation)  
20. Subject is eligible for surgical resection 
Imaging Exclusion 
21. Targeted tumor(s) treatment volume overlaps a non-targeted tumor visible via 
imaging 
22. The targeted tumor(s) is not clearly visible with diagnostic ultrasound and 
computed tomography (CT) or magnetic resonance (MR) imaging 
23. The targeted tumor(s) is located in liver segment 1 
24. The Planned Treatment Volume intended to cover the targeted tumor includes or 
encompasses any portion of the main portal vein, common hepatic duct, common 
bile duct, gallbladder or stomach/bowel. 
Statistical Methods 
The primary efficacy and safety endpoints are based on a comparison to pre-specified 
performance goals established from relevant literature.  
Primary Efficacy 
A lesion success performance goal of 70% was established and the hypothesis was as 
follows: 
Null hypothesis: HistoSonics technical success rate ≤70% 
Alternative hypothesis: HistoSonics technical success rate >70% 
The proportion of observed Technical Success by lesion on those with evaluable imaging 
will be reported. As up to 3 treated lesions are allowed per subject, the 95% confidence 
interval for the observed Technical Success rate will be estimated by the bootstrap 
sampling with replacement method to account for potential within-subject lesion 
correlations.  A subject will be the bootstrap sampling unit.  A > 70% lower limit for the 
95% confidence interval will indicate the HistoSonics Technical Success rate as 
statistically significantly higher than the performance goal of 70% at a 1-sided p < 0.025 
level.   
Primary Safety 
A safety performance goal of 25% was established and the hypothesis was as follows: 
Null hypothesis: HistoSonics major complications patient incidence rate ≥25% 
Alternative hypothesis: HistoSonics major complications patient incidence rate 
<25% 
The patient incidence rate of index-procedure related major complications and its two-
sided 95% Wilson Score CI will be calculated based on all subjects enrolled. The upper 

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
6 
 
limit of the 95% CI must be <25% in order to regard the index procedure’s safety as 
acceptable. 
Secondary endpoints will be presented descriptively with no hypothesis test. 
Determination of Sample Size 
A literature review was conducted to identify rates of technical success in published 
studies on microwave and radiofrequency ablation of primary and metastatic liver 
tumors from 2010 to 2020. Eight studies reporting on 2,876 total tumors were assessed 
with a mean, weighted mean, and median rate of 81.5%, 86.6%, and 92.0%, 
respectively1–8. Sample size was determined from primary efficacy of technical success 
assuming one treated lesion per subject for simplicity. Forty evaluable subjects were 
targeted for enrollment. Using a technical success acceptance level of 85% (34/40 
lesions), which is consistent with the literature review results, the Wilson Score 95% 
confidence interval is 70.9% to 92.9%. Using the lower limit of the 95% confidence 
interval, a null hypothesis of ≤70% success rate can be rejected at a 1-sided p<0.025 
significance level. By binomial probability calculation, the false positive (alpha) error for 
this design is 0.024. Assuming a true histotripsy technical success rate of 90%, the power 
for observing ≥34/40=85% in the trial is approximately 0.90. Due to the allowance of up 
to three (3) treated lesions per subject, the actual 95% confidence interval for the lesion 
based technical success rate would be estimated by the bootstrap sampling with 
replacement method and subject would be the sampling unit. The confidence interval 
would be narrower, and the power would be higher than the above estimates.  
A similar review of major complications (CTCAE grade 3 or higher equivalent) when 
treating liver lesions with radiofrequency ablation identified 5 independent studies 
reporting on 1,935 patients and one review article encompassing 32 studies1–5,9. Major 
complication rates ranged from 2.0% to 11.2%. For a new technology such as histotripsy, 
a conservative assumption for major complications was assumed to be close to the 
upper end of the literature results of 11.2%. Accordingly, with the sample size of 40 
participants and a histotripsy major complication rate of 10% (4/40 participants), the 
Wilson Score 95% confidence interval is 4.0% to 23.1%. Assuming a true histotripsy 
event rate of 7%, the power of observing <4/40=10% in the trial is approximately 0.85. 
A 5% - 10% attrition rate was anticipated; reasons for attrition included: both 
anticipated and unanticipated drop-out (e.g., subject withdrawal, loss-to-follow-up, and 
death) as well as the inability for the Core Laboratory to assess the primary efficacy 
endpoint due to missing or non-evaluable imaging. Therefore, up to forty-five (45) 
subjects were targeted for enrollment; subject replacement was not applicable in these 
cases. 
Bibliography 
1. SolbiaƟ L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal 
metastases treated with percutaneous radiofrequency ablaƟon: local response rate 
and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958-968. 
doi:10.1148/radiol.12111851 
2. Kim Y sun, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency 
ablaƟon as ﬁrst-line therapy of early hepatocellular carcinoma: analysis of prognosƟc 
factors. J Hepatol. 2013;58(1):89-97. doi:10.1016/j.jhep.2012.09.020 
3. Shady W, Petre EN, Gonen M, et al. Percutaneous Radiofrequency AblaƟon of 
Colorectal Cancer Liver Metastases: Factors AﬀecƟng Outcomes--A 10-year 

 
#HOPE4LIVER EU/UK Protocol Synopsis 
NCT04573881 
 
7 
 
Experience at a Single Center. Radiology. 2016;278(2):601-611. 
doi:10.1148/radiol.2015142489 
4. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes AŌer StereotacƟc Body Radiotherapy 
or Radiofrequency AblaƟon for Hepatocellular Carcinoma. J Clin Oncol. 
2016;34(5):452-459. doi:10.1200/JCO.2015.61.4925 
5. Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. TherapeuƟc eﬃcacy of percutaneous 
radiofrequency ablaƟon versus microwave ablaƟon for hepatocellular carcinoma. 
PLoS One. 2013;8(10):e76119. doi:10.1371/journal.pone.0076119 
6. Pompili M, Saviano A, de Mathaeis N, et al. Long-term eﬀecƟveness of resecƟon and 
radiofrequency ablaƟon for single hepatocellular carcinoma ≤3 cm. Results of a 
mulƟcenter Italian survey. J Hepatol. 2013;59(1):89-97. 
doi:10.1016/j.jhep.2013.03.009 
7. Hamada A, Yamakado K, Nakatsuka A, et al. Radiofrequency ablaƟon for colorectal 
liver metastases: prognosƟc factors in non-surgical candidates. Jpn J Radiol. 
2012;30(7):567-574. doi:10.1007/s11604-012-0089-0 
8. Bale R, Widmann G, Schullian P, et al. Percutaneous stereotacƟc radiofrequency 
ablaƟon of colorectal liver metastases. Eur Radiol. 2012;22(4):930-937. 
doi:10.1007/s00330-011-2314-0 
9. Lahat E, Eshkenazy R, Zendel A, et al. ComplicaƟons aŌer percutaneous ablaƟon of 
liver tumors: a systemaƟc review. Hepatobiliary Surg Nutr. 2014;3(5):317-323. 
doi:10.3978/j.issn.2304-3881.2014.09.07 
Sponsor 
HistoSonics, Inc. 
16305 36th Avenue North, Suite 300 
Plymouth, MN 55446 
United States of America (USA) 
Fax: +1 734-929-9020